Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$2,068 Mln
P/E Ratio
--
P/B Ratio
5.7
Industry P/E
--
Debt to Equity
0.27
ROE
-0.46 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-1.51
CFO
$-150.74 Mln
EBITDA
$-596.71 Mln
Net Profit
$-794.68 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Novocure (NVCR)
| -38.62 | -3.02 | -28.47 | 44.76 | -38.12 | -24.15 | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Novocure (NVCR)
| -79.65 | -2.30 | -56.61 | 105.34 | 151.70 | 65.29 | 157.32 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China,... and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland. Address: Neuhofstrasse 21, Baar, Switzerland, 6340 Read more
Executive Chairman
Mr. William F. Doyle
Executive Chairman
Mr. William F. Doyle
Headquarters
Baar
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Novocure Ltd (NVCR) stood at $ 1,992 Mln as on 31-Mar-25
The share price of Novocure Ltd (NVCR) is $18.29 (NASDAQ) as of 29-Apr-2025 16:00 EDT. Novocure Ltd (NVCR) has given a return of -38.12% in the last 3 years.
Novocure Ltd (NVCR) has a market capitalisation of $ 2,068 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Novocure Ltd (NVCR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Novocure Ltd (NVCR) and enter the required number of quantities and click on buy to purchase the shares of Novocure Ltd (NVCR).
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland. Address: Neuhofstrasse 21, Baar, Switzerland, 6340
The CEO & director of Mr. William F. Doyle. is Novocure Ltd (NVCR), and CFO & Sr. VP is Mr. William F. Doyle.
There is no promoter pledging in Novocure Ltd (NVCR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Novocure Ltd (NVCR) | Ratios |
|---|---|
|
Return on equity(%)
|
-45.43
|
|
Operating margin(%)
|
-12.76
|
|
Net Margin(%)
|
-26.41
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Novocure Ltd (NVCR) was $0 Mln.
$-0.02
(
